📣 VC round data is live. Check it out!

BGI Genomics Valuation Multiples

Discover revenue and EBITDA valuation multiples for BGI Genomics and similar public comparables like Genus, Insight Lifetech, Tecan Group, Neogen and more.

BGI Genomics Overview

About BGI Genomics

BGI Genomics Co Ltd is a China-based company principally engaged in the provision of genomic class diagnosis and research services through the application of biotechnology. It offers its services in various research areas, such as agriculture and food science, cancer research, metagenomics, reproductive health, biomarker discovery, and drug discovery. The company mainly provides services for domestic and overseas academic institutions hospitals, medical institutions and others.


Founded

2010

HQ

China

Employees

N/A

Website

bgi.com

Financials (LTM)

Revenue: $556M
EBITDA: $47M

EV

$2B

Valuation Multiples

Start free trial

Valuation Multiples for 15K+ Public Comps

AdidasAirbnbAmazonCiscoCoca-ColaDellDropboxIBMIntelMcDonaldsNikeNVIDIASamsungSpotifyTeslaToyota
Browse Valuation Multiples

BGI Genomics Financials

BGI Genomics reported last 12-month revenue of $556M and EBITDA of $47M.

In the same LTM period, BGI Genomics generated $206M in gross profit, $47M in EBITDA, and had net loss of ($52M).

Revenue (LTM)


BGI Genomics P&L

In the most recent fiscal year, BGI Genomics reported revenue of $548M and EBITDA of $43M.

BGI Genomics is unprofitable as of last fiscal year, with gross margin of 38%, EBITDA margin of 8%, and net margin of (16%).

See analyst estimates for BGI Genomics
LTMLast FY202320242025202620272028
Revenue$556M$548M$643M$572M$548M
Gross Profit$206M$206M$321M$237M$206M
Gross Margin37%38%50%41%38%
EBITDA$47M$43M$95M($52M)($7M)
EBITDA Margin9%8%15%(9%)(1%)
EBIT Margin(9%)(5%)5%(11%)(5%)
Net Profit($52M)($90M)$14M($133M)($91M)
Net Margin(9%)(16%)2%(23%)(17%)

Financial data powered by Morningstar, Inc.

BGI Genomics Stock Performance

BGI Genomics has current market cap of $2B, and enterprise value of $2B.

Market Cap Evolution


BGI Genomics' stock price is $5.38.

BGI Genomics share price decreased by 0.9% in the last 30 days, and by 25.6% in the last year.

BGI Genomics has an EPS (earnings per share) of $-0.22.

See more trading valuation data for BGI Genomics
EVMarket CapPrice 1DPrice 1MPrice 3MPrice 12MEPS
$2B$2B-0.9%-0.9%-8.0%-25.6%$-0.22

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.

Start Free Trial

BGI Genomics Valuation Multiples

BGI Genomics trades at 3.3x EV/Revenue multiple, and 39.0x EV/EBITDA.

See NTM and 2027E valuation multiples for BGI Genomics

EV / Revenue (LTM)


BGI Genomics Financial Valuation Multiples

As of June 2, 2026, BGI Genomics has market cap of $2B and EV of $2B.

BGI Genomics has a P/E ratio of (42.9x).

LTMLast FY202320242025202620272028
EV/Revenue3.3x3.4x2.9x3.2x3.4x
EV/EBITDA39.0x42.7x19.4x(35.6x)n/m
EV/EBIT(36.9x)(73.3x)53.9x(30.5x)(73.3x)
EV/Gross Profit9.0x8.9x5.7x7.8x8.9x
P/E(42.9x)(24.9x)163.9x(16.9x)(24.7x)
EV/FCF-(21.9x)(15.1x)(28.7x)(21.9x)

Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Verified BGI Genomics Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.

FactSetMorningstar
Start Free Trial

BGI Genomics Margins & Growth Rates

BGI Genomics grew revenue by 5% and EBITDA by 23% in the last fiscal year.

In the most recent fiscal year, BGI Genomics reported gross margin of 38%, EBITDA margin of 8%, and net margin of (16%).

See estimated margins and future growth rates for BGI Genomics

BGI Genomics Margins

Last FY202420252026202720282029
Gross Margin38%41%38%36%
EBITDA Margin8%(9%)(1%)9%
EBIT Margin(5%)(11%)(5%)0%
Net Margin(16%)(23%)(17%)(0%)
FCF Margin(15%)(11%)(15%)-

BGI Genomics Growth Rates

FY+1/FY23/2424/2525/2626/2727/2828/29
Revenue Growth5%(11%)(4%)5%
Gross Profit Growth1%(26%)(13%)1%
EBITDA Growth23%(154%)(86%)(840%)
EBIT Growth(105%)(277%)(58%)(105%)
Net Profit Growth(100%)(1072%)(32%)(100%)
FCF Growth-(48%)31%-

Data powered by FactSet, Inc. and Morningstar, Inc.

BGI Genomics Operational KPIs

BGI Genomics' Rule of 40 is 14% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

BGI Genomics' Rule of X is 21% (created by Bessemer, Rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

Access forward-looking KPIs for BGI Genomics
LTMLast FY202320242025202620272028
Rule of 4015%14%---
Bessemer Rule of X24%21%---
S&M Expenses to Revenue-11%12%14%11%
G&A Expenses to Revenue9%9%3%4%3%
R&D Expenses to Revenue-12%12%16%12%
Opex to Revenue-42%45%52%42%

Data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 230+ Verticals

BGI Genomics Competitors

BGI Genomics competitors include Genus, Insight Lifetech, Tecan Group, Neogen, GRAIL, Dr. Lal PathLabs, Dian Diagnostics Group, Fleury, GeneDx and MGI Tech.

Most BGI Genomics public comparables operate across Diagnostics & Genomics, Laboratory Services, BioTech and DeepTech.

EV/RevenueEV/EBITDA
Last FYLTM2027ELast FYLTM2027E
Genus2.6x2.6x14.5x13.2x
Insight Lifetech29.3x-131.9x-
Tecan Group2.1x2.1x14.0x13.9x
Neogen2.9x3.0x14.0x14.8x
GRAIL13.5x12.4x(5.3x)(5.7x)
Dr. Lal PathLabs10.2x8.9x31.9x31.4x
Dian Diagnostics Group1.2x1.2x13.2x11.5x
Fleury1.4x1.4x4.9x5.4x

This data is available for Pro users. Sign up to see all BGI Genomics competitors and their valuation data.

Start Free Trial

Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples

Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.

Start Free Trial

About BGI Genomics

When was BGI Genomics founded?BGI Genomics was founded in 2010.
Where is BGI Genomics headquartered?BGI Genomics is headquartered in China.
Is BGI Genomics publicly listed?Yes, BGI Genomics is a public company listed on Shenzhen Stock Exchange.
What is the stock symbol of BGI Genomics?BGI Genomics trades under 300676 ticker.
When did BGI Genomics go public?BGI Genomics went public in 2017.
Who are competitors of BGI Genomics?BGI Genomics main competitors include Genus, Insight Lifetech, Tecan Group, Neogen, GRAIL, Dr. Lal PathLabs, Dian Diagnostics Group, Fleury, GeneDx, MGI Tech.
What is the current market cap of BGI Genomics?BGI Genomics' current market cap is $2B.
What is the current revenue of BGI Genomics?BGI Genomics' last 12 months revenue is $556M.
What is the current revenue growth of BGI Genomics?BGI Genomics revenue growth (NTM/LTM) is 6%.
What is the current EV/Revenue multiple of BGI Genomics?Current revenue multiple of BGI Genomics is 3.3x.
What is the current EBITDA of BGI Genomics?BGI Genomics' last 12 months EBITDA is $47M.
What is BGI Genomics' EBITDA margin?BGI Genomics' last 12 months EBITDA margin is 9%.
What is the current EV/EBITDA multiple of BGI Genomics?Current EBITDA multiple of BGI Genomics is 39.0x.
How many companies BGI Genomics has acquired to date?BGI Genomics hasn't acquired any companies yet (or none have been disclosed publicly).
In how many companies BGI Genomics has invested to date?BGI Genomics hasn't invested in any companies yet (or none have been disclosed publicly).

See public comps similar to BGI Genomics

Lists including BGI Genomics

Start Your
Free Trial Today

Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.

Start Trial